Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorSakin, Önder
dc.contributor.authorAngın, Ali Doğukan
dc.contributor.authorOruç, Muhammet Ali
dc.contributor.authorAkalın, Emine Eda
dc.contributor.authorÇıkman, Muzaffer Seyhan
dc.contributor.authorBasak, Kayhan
dc.contributor.authorAlan, Yasemin
dc.contributor.authorKaptanagasi, Asuman Orcun
dc.contributor.authorAlan, Murat
dc.contributor.authorÖktem, Abdülmecit
dc.date.accessioned2025-01-24T07:00:27Z
dc.date.available2025-01-24T07:00:27Z
dc.date.issued2021en_US
dc.identifier.citationAnğın, A. D., Oruç, M. A., Sakin, Ö., Akalın, E. E., Çıkman, M., Başak, K., ... & Alan, M. (2021). Evaluation of protective effects of mirtazapine and mesna on cisplatin-induced ovarian damage in rats. Journal of Experimental and Clinical Medicine, 38(2), 72-81.en_US
dc.identifier.issn13094483
dc.identifier.urihttps://10.52142/omujecm.38.2.4
dc.identifier.urihttps://hdl.handle.net/20.500.12513/7060
dc.description.abstractTo evaluate whether mirtazapine and mesna have protective effects on cisplatin-induced ovarian injury. A total of 32 female Wistar Albino rats were divided into 4 groups (8 rats per group) and included in the study. No medication was administered to the first group; only intervention was that their ovaries were removed and anti-mullerian hormone (AMH) values were measured. The second group received intramuscular cisplatin at a single dose of 7.5 mg/kg. The third group received a single dose of 200 mg/kg mesna intraperitoneally, and 30 minutes later, a single dose of 7.5 mg/kg intramuscular cisplatin was administered. The fourth group received oral 30 mg/kg mirtazapine, and 60 minutes later, a single dose of 7.5 mg/kg intramuscular cisplatin was administered. Oral 30 mg/kg mirtazapine was continued for ten days. Ovaries and AMH values of all groups were evaluated at the end of tenth day. In the cisplatin group when compared to normal ovarian tissue total histopathological damage score increased (p=0.037), preantral follicle count decreased (p=0.003) and AMH levels decreased (p<0.001). In the cisplatin + mesna group total ovarian damage score was also increased (p=0.005), preantral and antral follicles decreased (p<0.001 and p=0.001, respectively), and AMH levels decreased (p<0.001). In the cisplatin + mirtazapine group, total ovarian damage score (p<0.001), preantral follicle count (p=0.002) and AMH values were decreased (p<0.001). It was concluded that mesna and mirtazapine were not effective in preventing ovarian damage due to cisplatin. © 2021 Ondokuz Mayis Universitesi. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherOndokuz Mayis Universitesien_US
dc.relation.isversionof10.52142/omujecm.38.2.4en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-mullerian Hormoneen_US
dc.subjectCisplatinen_US
dc.subjectMesnaen_US
dc.subjectMirtazapineen_US
dc.subjectOvaryen_US
dc.subjectRatsen_US
dc.titleEvaluation of Protective Effects of Mirtazapine and Mesna on Cisplatin-İnduced Ovarian Damage in Ratsen_US
dc.typearticleen_US
dc.relation.journalJournal of Experimental and Clinical Medicine (Turkey)en_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorIDMuhammet Ali Oruç / 0000-0002-4320-8579en_US
dc.identifier.volume38en_US
dc.identifier.issue2en_US
dc.identifier.startpage72en_US
dc.identifier.endpage81en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster